JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $47 to $50.
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $47 to $50.